Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: The optimal subsequent treatment and the determinants of survival after sorafenib–regorafenib failure in patients with hepatocellular carcinoma (HCC) remain unclear. The aim of this study was to delineate the determinants of response and survival after regorafenib and evaluate the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, I-Cheng, Chao, Yee, Lee, Pei-Chang, Chen, San-Chi, Chi, Chen-Ta, Wu, Chi-Jung, Wu, Kuo-Cheng, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030368/
https://www.ncbi.nlm.nih.gov/pubmed/35454919
http://dx.doi.org/10.3390/cancers14082014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030368/
https://www.ncbi.nlm.nih.gov/pubmed/35454919
http://dx.doi.org/10.3390/cancers14082014

Ejemplares similares